LT3607069T - Produktai ir kompozicijos - Google Patents

Produktai ir kompozicijos

Info

Publication number
LT3607069T
LT3607069T LTEPPCT/EP2018/058766T LT18058766T LT3607069T LT 3607069 T LT3607069 T LT 3607069T LT 18058766 T LT18058766 T LT 18058766T LT 3607069 T LT3607069 T LT 3607069T
Authority
LT
Lithuania
Prior art keywords
compositions
products
Prior art date
Application number
LTEPPCT/EP2018/058766T
Other languages
English (en)
Inventor
Judith HAUPTMANN
Dmitry Samarsky
Christian Frauendorf
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61899311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3607069(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1707203.4A external-priority patent/GB201707203D0/en
Priority claimed from GBGB1708397.3A external-priority patent/GB201708397D0/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of LT3607069T publication Critical patent/LT3607069T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
LTEPPCT/EP2018/058766T 2017-04-05 2018-04-05 Produktai ir kompozicijos LT3607069T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17165129 2017-04-05
GBGB1707203.4A GB201707203D0 (en) 2017-05-05 2017-05-05 Modified positions
GBGB1708397.3A GB201708397D0 (en) 2017-05-25 2017-05-25 Modified positions
EP17201352 2017-11-13
PCT/EP2018/058766 WO2018185241A1 (en) 2017-04-05 2018-04-05 Products and compositions

Publications (1)

Publication Number Publication Date
LT3607069T true LT3607069T (lt) 2023-01-10

Family

ID=61899311

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/058766T LT3607069T (lt) 2017-04-05 2018-04-05 Produktai ir kompozicijos

Country Status (16)

Country Link
US (3) US11015198B2 (lt)
EP (2) EP3607069B1 (lt)
JP (3) JP7155239B2 (lt)
CN (1) CN110520531A (lt)
AU (1) AU2018247925B2 (lt)
DK (1) DK3607069T3 (lt)
ES (1) ES2932831T3 (lt)
FI (1) FI3607069T3 (lt)
HR (1) HRP20221400T1 (lt)
HU (1) HUE061247T2 (lt)
IL (2) IL268828B2 (lt)
LT (1) LT3607069T (lt)
PL (1) PL3607069T3 (lt)
RS (1) RS63836B1 (lt)
SI (1) SI3607069T1 (lt)
WO (1) WO2018185241A1 (lt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts CONJUGATE OLIGONUCLEOTIDES
SI3607069T1 (sl) 2017-04-05 2023-02-28 Silence Therapeutics Gmbh Produkti in sestavki
US11414660B2 (en) 2017-04-05 2022-08-16 Silence Therapeutics Gmbh Products and compositions
FI3607068T3 (fi) * 2017-04-05 2023-02-19 TMPRSS6:n RNA-interferenssivälitteinen inhibitio
EP3483269A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
HUE061265T2 (hu) 2017-11-13 2023-06-28 Silence Therapeutics Gmbh Nukleinsavak LPA expressziójának gátlására sejtben
WO2019105418A1 (zh) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
CN111601891A (zh) 2018-01-16 2020-08-28 迪克纳制药公司 用于抑制aldh2表达的组合物和方法
EP3598995A1 (en) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113227372A (zh) 2018-11-13 2021-08-06 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
TW202043471A (zh) * 2019-01-16 2020-12-01 美商健贊公司 ＳＥＲＰＩＮＣ１ ｉＲＮＡ組成物及其使用方法
JP2022523467A (ja) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ 動的な薬物動態を修飾するアンカー
WO2020206350A1 (en) * 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
US20210115442A1 (en) * 2019-08-23 2021-04-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
IL292391A (en) * 2019-10-24 2022-06-01 Genevant Sciences Gmbh Bracelets and methods for treating acromegaly
JP2023515664A (ja) * 2020-03-06 2023-04-13 アリゴス セラピューティクス，インコーポレーテッド 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用
WO2022060871A1 (en) 2020-09-15 2022-03-24 Verve Therapeutics, Inc. Lipid formulations for gene editing
JP2023547512A (ja) 2020-11-04 2023-11-10 ウニベルジテート ベルン 細胞におけるｐｒｏｓ１の発現を阻害するための核酸
KR20230134509A (ko) * 2021-01-22 2023-09-21 알닐람 파마슈티칼스 인코포레이티드 변형 이중 가닥 올리고뉴클레오타이드
WO2022184852A1 (en) * 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
CN117597133A (zh) * 2021-03-24 2024-02-23 阿塔兰塔治疗公司 具有模式化化学修饰的双链siRNA
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EP4493570A2 (en) 2022-03-16 2025-01-22 Empirico Inc. Galnac compositions for improving sirna bioavailability
AU2023245603A1 (en) 2022-03-28 2024-11-07 Empirico Inc. Modified oligonucleotides
WO2024200512A1 (en) 2023-03-27 2024-10-03 Silence Therapeutics Gmbh Compounds and compositions for use in stem cell transplantation
TW202500745A (zh) * 2023-05-26 2025-01-01 大陸商維亞臻生物技術（蘇州）有限公司 一種用於代謝疾病的雙鏈核苷酸化合物及其應用
CN119464281A (zh) * 2023-08-09 2025-02-18 北京福元医药股份有限公司 抑制DGAT2基因表达的siRNA、siRNA缀合物或其前药和药物组合物及用途
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2006279454B2 (en) 2005-08-17 2011-12-15 Sirna Therapeutics, Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2007112414A2 (en) * 2006-03-27 2007-10-04 Isis Pharmaceuticals, Inc. Conjugated double strand compositions for use in gene modulation
US20110046206A1 (en) * 2007-06-22 2011-02-24 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
CA2708153C (en) 2007-12-04 2017-09-26 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
JP2011511004A (ja) 2008-01-31 2011-04-07 アルナイラム ファーマシューティカルズ インコーポレイテッド ＰＣＳＫ９遺伝子を標的とするｄｓＲＮＡを送達するための最適化された方法
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
US8962580B2 (en) 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
WO2012094115A1 (en) 2010-12-17 2012-07-12 Arrowhead Research Corporation Compositions and methods for inhibiting expression of flt3 genes
JP2014522242A (ja) * 2011-06-06 2014-09-04 メルク・シャープ・アンド・ドーム・コーポレーション イソクエン酸デヒドロゲナーゼ（ｉｄｈ１）遺伝子発現のｒｎａ干渉媒介抑制
TWI695066B (zh) 2011-06-30 2020-06-01 美商艾羅海德製藥公司 用於抑制b型肝炎病毒基因表現之組合物及方法
PT3301177T (pt) 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
WO2013074974A2 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Modified rnai agents
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CA2892160C (en) * 2012-12-05 2021-03-23 Anna Borodovsky Pcsk9 irna compositions and methods of use thereof
RS60796B1 (sr) * 2013-05-01 2020-10-30 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije apolipoproteina (a)
TWI727917B (zh) * 2013-05-22 2021-05-21 美商阿尼拉製藥公司 ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2015188194A1 (en) 2014-06-06 2015-12-10 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
WO2016149020A1 (en) 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
EP3271482A4 (en) 2015-03-17 2019-02-13 Arrowhead Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING THE GENE EXPRESSION OF FACTOR XII
SI3277814T1 (sl) 2015-04-03 2020-12-31 University Of Massachusetts Oligonukleotidne spojine za ciljanja MRNA huntingtina
US20160319278A1 (en) * 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
CA3023764A1 (en) 2016-06-06 2017-12-14 Arrowhead Pharmaceuticals, Inc. 5'-cyclo-phosphonate modified nucleotides
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
IL267959B2 (en) 2017-01-10 2024-07-01 Arrowhead Pharmaceuticals Inc Alpha-1 antitrypsin (AAT) RNAi agents, preparations containing AAT RNAi agents and their uses
AU2018213379A1 (en) 2017-01-30 2019-07-18 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibition of factor XII gene expression
SI3607069T1 (sl) 2017-04-05 2023-02-28 Silence Therapeutics Gmbh Produkti in sestavki
FI3607068T3 (fi) * 2017-04-05 2023-02-19 TMPRSS6:n RNA-interferenssivälitteinen inhibitio
US10597657B2 (en) 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
CN111343994B (zh) 2017-09-14 2023-11-21 箭头药业股份有限公司 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法
HUE061265T2 (hu) * 2017-11-13 2023-06-28 Silence Therapeutics Gmbh Nukleinsavak LPA expressziójának gátlására sejtben
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
CN113227372A (zh) * 2018-11-13 2021-08-06 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸

Also Published As

Publication number Publication date
DK3607069T3 (da) 2022-11-21
JP2024147806A (ja) 2024-10-16
AU2018247925B2 (en) 2024-06-06
EP3607069A1 (en) 2020-02-12
JP7155239B2 (ja) 2022-10-18
HRP20221400T1 (hr) 2023-01-06
AU2018247925A1 (en) 2019-10-03
FI3607069T3 (fi) 2023-01-13
SI3607069T1 (sl) 2023-02-28
JP2022173554A (ja) 2022-11-18
IL268828B2 (en) 2025-11-01
CA3057565A1 (en) 2018-10-11
CN110520531A (zh) 2019-11-29
ES2932831T3 (es) 2023-01-26
JP7583005B2 (ja) 2024-11-13
EP3607069B1 (en) 2022-11-02
IL268828B1 (en) 2025-07-01
IL268828A (en) 2019-10-31
US20220090067A1 (en) 2022-03-24
EP4219713A2 (en) 2023-08-02
JP2020516312A (ja) 2020-06-11
WO2018185241A1 (en) 2018-10-11
PL3607069T3 (pl) 2023-03-06
US20250043288A1 (en) 2025-02-06
IL321221A (en) 2025-07-01
HUE061247T2 (hu) 2023-06-28
US20200095580A1 (en) 2020-03-26
US11015198B2 (en) 2021-05-25
RS63836B1 (sr) 2023-01-31
US12084656B2 (en) 2024-09-10
EP4219713A3 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
LT3607069T (lt) Produktai ir kompozicijos
IL268970A (en) New preparations and methods
IL271275A (en) Preparations containing coronas and their uses
SI3580561T1 (sl) Metode, osnovane na hla, in njihove sestave ter uporabe
IL269576A (en) products and vehicles
IL269517A (en) compounds and products
SG11201707876YA (en) Microalgal compositions and uses thereof
GB201807325D0 (en) Compositions and methods
GB202201860D0 (en) Novel methods and compositions
PT3458509T (pt) Produtos de alumina e uso dos mesmos em composições de polímero com alta condutividade térmica
IL274524A (en) Preparations and methods for aquaculture
GB201710288D0 (en) Products and methods
GB201502002D0 (en) Uses and compositions
ZA202004533B (en) Skin-brightening compositions and methods
SG11202002224XA (en) Composition and uses thereof
GB201608762D0 (en) Compositions and uses thereof
GB201501991D0 (en) Uses and compositions
GB201502026D0 (en) Uses and compositions
PL3568203T3 (pl) Związki i kompozycje
IL271469A (en) Hemostatic products
GB201712592D0 (en) Novel compositions and uses thereof
GB201614897D0 (en) Compositions and uses thereof
GB201511886D0 (en) Uses and compositions
GB201812952D0 (en) Compositions and uses thereof
GB201602409D0 (en) Compositions and uses thereof